The COVID-19 pandemic caused by novel severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) is responsible for more than 500 million cases worldwide as of April 2022 …

Coronavirus disease 2019 in children presents with milder clinical manifestations than in
adults. On the other hand, the presence of a wide range of inflammatory manifestations …

Background: Cases of adolescents and young adults develo** myocarditis after
vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–targeted …

The Pfizer-BioNTech vaccine, currently authorized for persons aged≥ 5 years, provides a
high level of protection against severe COVID-19 in persons aged 12–18 years. Vaccine …

Background Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory
condition associated with antecedent SARS-CoV-2 infection. In the USA, reporting of MIS-C …

Methods| This population-based cohort study prospectively included patients aged 0 to 17
years with MIS-C from all 18 Danish pediatric departments. Patients were diagnosed from …

Background Although severe acute COVID-19 is rare in children, SARS-CoV-2 infection can
trigger the novel post-infectious condition multisystem inflammatory syndrome in children …

Background Multisystem inflammatory syndrome in children (MIS-C) is the most severe
clinical entity associated with pediatric SARS-CoV-2 infection with a putative role of the …

Background Although paediatric clinical presentations of COVID-19 are usually less severe
than in adults, serious illness and death have occurred. Many countries started the …

Objective To review whether the current COVID-19 vaccines can prevent the occurrence of
multisystem inflammatory syndrome in children (MIS-C) and adolescents. Methods A …